Animal studies indicating that Aβimmunization of APP transgenic mice reduced plaque burden in mice stimulatedhuman clinical trials designed to evaluate the clinical efficacy of Aβimmunization in the treatment of AD. Here, APP is linked to Alzheimer disease.